
|Videos|December 13, 2022
Dr. Hafron highlights the most significant prostate cancer treatment advances in 2022
Author(s)Urology Times staff
Advertisement
In this interview, Jason M. Hafron, MD, recaps the biggest advances in the prostate cancer treatment paradigm in 2022. Hafron is a partner at the Michigan Institute of Urology, PC; an associate professor of Urology at the William Beaumont School of Medicine, Oakland University; and the director of Robotic Surgery at Beaumont Hospital Royal Oak in Michigan.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Team-based AE protocols improve consistency with the gemcitabine intravesical therapy system
2
Practical tips for AE management with the gemcitabine intravesical system
3
Study to assess adaptive-dosed 177Lu-DOTA-HYNIC-panPSMA in mHSPC
4
First-in-human bladder transplant demonstrates sustained function at 6 months
5












